Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6
From Hematologic Oncology Update · 32:31
Show by Dr. Neil Love
Featuring perspectives from Dr Lindsey Roeker, including the following topics:Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)CME information and select publications
More episodes of Hematologic Oncology Update
More episodes
- Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens
- Diffuse Large B-Cell Lymphoma — A Grand Rounds Program
- Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis
- Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5
- Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome
- Chronic Lymphocytic Leukemia — Microlearning Activity 2
- Chronic Lymphocytic Leukemia — Microlearning Activity 1
- Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
- Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
- Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.